Selected article for: "clinical isolate and mucin expression"

Author: Van der Gucht, Winke; Stobbelaar, Kim; Govaerts, Matthias; Mangodt, Thomas; Barbezange, Cyril; Leemans, Annelies; De Winter, Benedicte; Van Gucht, Steven; Caljon, Guy; Maes, Louis; De Dooy, Jozef; Jorens, Philippe; Smet, Annemieke; Cos, Paul; Verhulst, Stijn; Delputte, Peter L.
Title: Isolation and Characterization of Clinical RSV Isolates in Belgium during the Winters of 2016–2018
  • Document date: 2019_11_6
  • ID: 0imlae98_49
    Snippet: We have isolated RSV from nasal samples from patients in the winter seasons of 2016-2017 and 2017-2018 and found that isolating infectious virus from nasal samples is most efficient from nasopharyngeal aspirates (50%) compared to nasopharyngeal swabs (27%). However, yield may also depend on timing of sampling compared to onset of symptoms and time between sampling and inoculation of cell culture. HEp-2 cells were used for isolation since they are.....
    Document: We have isolated RSV from nasal samples from patients in the winter seasons of 2016-2017 and 2017-2018 and found that isolating infectious virus from nasal samples is most efficient from nasopharyngeal aspirates (50%) compared to nasopharyngeal swabs (27%). However, yield may also depend on timing of sampling compared to onset of symptoms and time between sampling and inoculation of cell culture. HEp-2 cells were used for isolation since they are permissive for most RSV strains and isolates described. One well-known exception is RSV B1, which infects HEp-2 cells, but viral titers remain low compared to other strains. However, infection of RSV B1 in Vero cells does yield a higher titer, which is also the case for the clinical isolate BE/ANT-B20/17 from this study. The clinical isolates were genotyped and characterized on their ability to grow and produce infectious virus in cell lines. Thermal stability was assessed at 37 °C (normal body temperature, incubation temperature), 32 °C (estimated nasal temperature) and 4 °C (storage temperature), fusion capacity and neutralization by palivizumab as specific features of the fusion protein and mucin mRNA expression of MUC1 and MUC4 as cell-tethered mucins, and MUC5AC and MUC5B as secreted mucins.

    Search related documents:
    Co phrase search for related documents
    • body temperature and cell culture inoculation sampling: 1
    • body temperature and cell line: 1
    • body temperature and cell tethered mucin: 1
    • body temperature and clinical isolate: 1, 2, 3
    • body temperature and clinical isolate ANT study case: 1
    • body temperature and fusion capacity: 1
    • body temperature and fusion protein: 1, 2
    • body temperature and incubation temperature: 1, 2
    • body temperature and incubation temperature normal body temperature: 1
    • body temperature and infectious virus: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • body temperature and infectious virus produce: 1
    • body temperature and inoculation sampling: 1
    • body temperature and low remain: 1
    • body temperature and mucin fusion protein: 1
    • body temperature and nasal temperature: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • body temperature and nasopharyngeal swab: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • body temperature and neutralization fusion capacity: 1
    • body temperature and normal body temperature: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75
    • body temperature and palivizumab neutralization fusion capacity: 1